期刊文献+

Leveraging metformin to combat hepatocellular carcinoma:its therapeutic promise against hepatitis viral infections

原文传递
导出
摘要 Hepatocellular carcinoma(HCC)is categorized among the most common primary malignant liver cancer and a primary global cause of death from cancer.HCC tends to affect males 2-4 times more than females in many nations.The main factors that raise the incidence of HCC are chronic liver diseases,hepatotropic viruses like hepatitis B(HBV)and C(HCV),non-alcoholic fatty liver disease,exposure to toxins like aflatoxin,and non-alcoholic steatohepatitis(NASH).Among these,hepatitis B and C are the most prevalent causes of chronic hepatitis globally.Metformin,which is made from a naturally occurring compound called galegine,derived from the plant Galega officinalis(G.officinalis),has been found to exhibit antitumor effects in a wide range of malignancies,including HCC.In fact,compared to patients on sulphonylureas or insulin,studies have demonstrated that metformin treatment significantly lowers the risk of HCC in patients with chronic liver disease.This article will first describe the molecular mechanism of hepatitis B and C viruses in the development of HCC.Then,we will provide detailed explanations about metformin,followed by a discussion of the association between metformin and hepatocellular carcinoma caused by the viruses mentioned above.
出处 《Journal of Cancer Metastasis and Treatment》 2024年第1期282-306,共25页 癌症转移与治疗(英文版)
  • 相关文献

参考文献7

二级参考文献67

  • 1Robert Flisiak,Jerzy Jaroszewicz,Tadeusz W Lapiski,Iwona Flisiak,Danuta Prokopowiczi.Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-β1,metalloproteinase-1,and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C[J].World Journal of Gastroenterology,2005,11(43):6833-6838. 被引量:7
  • 2Ewa Janczewska-Kazek,Bogdan Marek,Dariusz Kajdaniuk,Halina BorgieI-Marek.Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1,vascular endothelial growth factor,and basic fibroblast growth factor in patients with chronic hepatitis C[J].World Journal of Gastroenterology,2006,12(6):961-965. 被引量:5
  • 3[1]Yoshida H,Shiratori Y,Moriyama M,Arakawa Y,Ide T,Sata M,Inoue O,Yano M,Tanaka M,Fujiyama S,Nishiguchi S,Kuroki T,Imazeki F,Yokosuka O,Kinoyama S,Yamada G,Omata M.Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan.IHIT Study Group.Inhibition of Hepatocarcinogenesis by Interferon Therapy.Ann Intern Med 1999; 131:174-181
  • 4[2]Camma C,Giunta M,Andreone P,Craxi A.Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:an evidence-based approach.J Hepatol 2001; 34:593-602
  • 5[3]Shiratori Y,Ito Y,Yokosuka O,Imazeki F,Nakata R,Tanaka N,Arakawa Y,Hashimoto E,Hirota K,Yoshida H,Ohashi Y,Omata M.Antiviral therapy for cirrhotic hepatitis C:association with reduced hepatocellular carcinoma development and improved survival.Ann Intern Med 2005; 142:105-114
  • 6[4]Hirashima N,Mizokami M,Orito E,Koide T,Itazu I,Kumada K,Sakakibara K,Kano H,Lau JY.Case report:development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response tointerferon-alpha.J Gastroenterol Hepatol 1996; 11:955-958
  • 7[5]Tamori A,Kuroki T,Nishiguchi S,Morimoto H,Morimoto M,Hirohashi K,Kinoshita AH,Kobayashi K.Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus.Hepatogastroenterology 1996; 43:1079-1083
  • 8[6]Kasahara A,Hayashi N,Mochizuki K,Takayanagi M,Yoshioka K,Kakumu S,Iijima A,Urushihara A,Kiyosawa K,Okuda M,Hino K,Okita K.Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C.Osaka Liver Disease Study Group.Hepatology 1998;27:1394-1402
  • 9[7]Miyano S,Togashi H,Shinzawa H,Sugahara K,Matsuo T,Takeda Y,Saito K,Saito T,Ishiyama S,Kaneko M,Takahashi T.Case report:Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C.J Gastroenterol Hepatol 1999; 14:928-930
  • 10[8]Yamaguchi K,Omagari K,Kinoshita H,Yoshioka S,Furusu H,Takeshima F,Nanashima A,Yamaguchi H,Kohno S.Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha.J Clin Gastroenterol 1999; 29:207-209

共引文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部